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ABSTRACT
Background: Choline is essential for infant nutrition, and breast
milk is a rich source of this nutrient. Common single nucleotide
polymorphisms (SNPs) change dietary requirements for choline
intake.
Objective: The aim of this study was to determine whether total
choline intake and/or SNPs influence concentrations of choline and
its metabolites in human breast milk and plasma.
Design: We gave a total of 103 pregnant women supplemental
choline or a placebo from 18 wk gestation to 45 d postpartum
and genotyped the women for 370 common SNPs. At 45 d post-
partum, we measured choline metabolite concentrations in breast
milk and plasma and assessed the dietary intake of choline by using
a 3-d food record.
Results: On average, lactating women in our study ate two-thirds of
the recommended intake for choline (Adequate Intake = 550 mg
choline/d). Dietary choline intake (no supplement) correlated with
breast-milk phosphatidylcholine and plasma choline concentrations.
A supplement further increased breast-milk choline, betaine, and
phosphocholine concentrations and increased plasma choline and
betaine concentrations. We identified 5 SNPs inMTHFR that altered
the slope of the intake–metabolite concentration relations, and we
identified 2 SNPs in PEMT that shifted these curves upward. Indi-
viduals who shared sets of common SNPs were outliers in plots of
intake–metabolite concentration curves; we suggest that these SNPs
should be further investigated to determine how they alter choline
metabolism.
Conclusion: Total intake of choline and genotype can influence
the concentrations of choline and its metabolites in the breast milk
and blood of lactating women and thereby affect the amount of
choline available to the developing infant. This study was regis-
tered at clinicaltrials.gov as NCT00678925. Am J Clin Nutr
2010;92:336–46.
INTRODUCTION
Breast milk is an important dietary source of choline for infants
during a time when choline is critically needed for growth and
development (1). Choline, or its metabolites, is needed for the
structural integrity and signaling functions of cell membranes;
choline is the major source of methyl groups in the diet (one of
choline’s metabolites, betaine, participates in the methylation of
homocysteine to form methionine), and choline directly affects
cholinergic neurotransmission, transmembrane signaling, and
lipid transport/metabolism (2). Also, choline influences brain
development and function (3–16). In humans, low choline intake
during pregnancy is associated with an increased risk of birth
defects in the fetus (17–19).
Choline can be derived from the diet (20) and from endogenous
biosynthesis [catalyzed by the enzyme phosphatidylethanolamine-
N-methyl transferase (PEMT)] (21–23). Many foods eaten by
humans contain choline and choline esters (20). The Institute of
Medicine (IOM) of the United States set an Adequate Intake (AI)
for choline of 550 mg choline/d for men, 425 mg choline/d for
women, and 550 mg choline/d for lactating women (24). Normal
choline intake in pregnant women in California ranges from half
the recommended intake (lowest quartile) to slightly more than
the recommended intake (highest quartile) (17), and similar dis-
tributions for choline intake in pregnant women were reported in
the National Health and Nutrition Examination Survey dataset
(25). During pregnancy, choline is made available to the fetus
across the placenta (26, 27), and after birth, human milk is a rich
source of choline for the developing infant (28, 29).
People differ in dietary choline requirements because of, in
part, common single nucleotide polymorphisms (SNPs) in genes
of choline and folate metabolism (30, 31). We hypothesized that
women with common SNPs that increase dietary requirements
for choline may need to consume diets higher in choline while
pregnant and lactating to optimally supply the choline needed to
support the developing nervous system of their children. To
investigate this, we enrolled 103 healthy pregnant women (at
18 wk gestation) who expressed the intention to breastfeed and
followed them through 45 d postpartum. One-half of the par-
ticipants received a choline supplement (as phosphatidylcholine),
and one-half of the participants received a placebo.We genotyped
these women for 370 SNPs in genes related to choline metab-
olism (such as the PEMT gene) and determined if the presence of
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these SNPs influenced breast-milk and plasma choline and
choline metabolite concentrations at 45 d postpartum across
a broad range of choline intake.
SUBJECTS AND METHODS
Participants
Healthy pregnant women at 18 wk gestation were recruited
for a protocol approved by the Institutional Review Board (IRB)
at the University of North Carolina (UNC) at Chapel Hill (in-
formed consent was obtained from all participants). The study
was advertised by using mass informational e-mails, IRB-
approved flyers or pamphlets displayed in target locations, and
advertisements in local newspapers. Of the initially recruited
140 participants, 103 participants completed the study per the
protocol, whereas 37 participants voluntarily dropped out or
were discharged for noncompliance. Participants ranged in age
from 21 to 41 y. The ethnic heritages of the 103 participants
were white American (89%), African American (3%), Asian
(6%), American Indian (1%), and other (1%), which reflected
the local population diversity of the greater Raleigh-Durham-
Chapel Hill metropolitan area.
For inclusion in the study, participants had to have a good state
of health, an uncomplicated, low-risk pregnancy, a prepregnancy
body mass index (in kg/m2) between 18 and 35, expressed the
intention to breastfeed for 90 d, received regular prenatal care,
taken a prenatal vitamin, and had fluency in English. Women
who used tobacco products, illicit drugs, alcohol, or were
pregnant with multiple fetuses were excluded.
Study design
This study was conducted as part of a larger ongoing study
aimed at investigating the effects of supplemental choline on
brain development and memory function. Upon entry into this
study, one-half of the participants was randomly assigned to
receive a choline supplement (6 PhosChol gelcaps/d (Nutrasal,
Westbrook, ME); each gelcap contained 900 mg phosphatidyl-
choline, which is equivalent to 125 mg choline; thus, 6 gelcaps
delivered 750 mg choline/d), and one-half of the participants was
randomly assigned to receive a placebo (6 gelcaps/d, each of
which contained 900 mg corn oil) from 18 wk pregnancy (on the
basis of their due date) through 90 d postpartum. This was done to
obtain a broader range of choline intake and to determinewhether
choline intake above the highest normal dietary intake was
needed to compensate for effects of SNPs. The choline sup-
plement used in this study was administered as phosphatidyl-
choline, and there are differences in the bioavailability between
free choline and phosphatidylcholine. Free choline is taken up
quickly and cleared from plasma quickly (3 h), whereas phos-
phatidylcholine increases plasma choline concentrations for
8–12 h with no appreciable change in plasma phosphatidyl-
choline concentrations (32, 33). Most of the choline consumed by
humans is in the form of phosphatidylcholine, but there are
several forms of choline in the diet.
Subjects were instructed to take 3 gelcaps in the morning with
breakfast and 3 capsules in the evening. Subjects were given
small calendar cards in a plastic sleeve on which they were
instructed to record their daily supplement or placebo intake.
Subjects came in for follow-up visits at 20 and 30 wk pregnancy
and 45 and 90 d postpartum. At each of these visits they were
asked to bring in any unused portion of capsules as well as their
supplement calendar. Capsule counts were done to assess
compliance and results compared with the intake recorded on the
calendars. Subjects were asked about any discrepancies. If
a discrepancy existed, the capsule count was used to estimate
compliance. Then, subjects were given a new supply of capsules
to carry them through the next study interval (except at the
90-d postpartum visit). At each visit, a 3-d food record and
a nonfasting blood sample were collected. Moreover, a first
morning breast-milk sample was collected at the 45- and 90-d
postpartum visits. Subjects continued to take supplements
through 90 d postpartum and the infants were tested at 10 and 12mo
of age as part of the larger study. However, data from only the
45-d postpartum visit is presented in the current study. This time
was chosen because breast milk has fully matured by this point,
and a greater number of subjects were breastfeeding (relative to
the 90-d postpartum time point).
All mothers and infants who participated in this study were
monitored for adverse events as detailed in a safety monitoring
plan. Specifically, upon enrollment, subjects were given an in-
formation packet to give to their obstetrician, which included
a letter requesting that the obstetrician notify us in the event that
any unusual or unexpected symptoms occur in the patient. Any
clinically significant symptoms that were reported to us by the
obstetrician were reported to the IRB as adverse events. In ad-
dition, a member of our study team contacted each subject by
e-mail or telephone every 4 wk to inquire about her overall health
and the progress of her pregnancy. A written questionnaire was
used for this purpose to ensure that the same data were collected
at each inquiry. All collected medical data were reviewed by the
study physician on a monthly basis. Moreover, all subjects were
advised to notify the study coordinator at any time should they
experience any unexpected health problem or complication. At
each follow-up visit, the subject’s vital signs, including weight
and blood pressure, were checked. Any clinically significant
findings noted at follow-up visits were also reported to the IRB as
adverse events. After subjects delivered, the study coordinator
contacted them to inquire about the well being of the mother and
the infant, and advised the subjects to notify the study team
should any major problems arise pertaining to the health or
development of their children. An interim safety analysis was
conducted in all adverse events once the first 50 infants had been
born and was reviewed by the UNC Data Safety and Monitoring
Board. The UNC Biomedical IRB also conducted a final safety
analysis of all adverse events once the study was complete.
Dietary analyses of choline intake
All participants were asked to keep a complete 3-d food record,
which was reflective of their usual intake, immediately before
their 45-d postpartum visit. Participants were asked to record
everything that they ate and drank on 2 typical weekdays and 1
weekend day. Daily food-intake records were analyzed with the
Esha Food Processor SQL program (Version 10.3; ESHA Re-
search, Salem, OR). This nutrient-analysis software references
the USDA National Nutrient Database and includes food values
for choline from the USDA Database for the Choline Content of
Common Foods (2008; http://www.nal.usda.gov/fnic/foodcomp/
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Data/Choline/Choln02.pdf). The software does not include val-
ues for betaine, a metabolite of choline. Hence, all known-food
betaine values (20) were manually entered into the database
before conducting the analyses, and referenced according to the
5-digit Nutrient Databank Number. The total choline content of
a food was calculated as the sum of the amounts of choline,
phosphocholine, glycerophosphocholine, phosphatidylcholine,
and sphingomyelin. Betaine was calculated independently. If the
total choline or betaine content of a specific food item was
unavailable, a nutritionally equivalent food was substituted in the
analysis. Each day of the 3-d food record was analyzed in-
dividually and averaged for each subject. The amount of choline
ingested on average per day was summed with the amount from
supplementation (750 or 0 mg) to arrive at an estimate of total
choline intake.
Determination of breast-milk and plasma choline
concentrations
Participants were asked to completely empty one breast of
milk uponwaking in the morning (between 0500 and 1000) on the
day of their 45-d postpartum visit with a mechanical or electric
pump that they supplied. This sample was mixed, and a 10-mL
aliquot was immediately frozen at 220C. Frozen milk samples
were transferred to our storage facility and stored at280C until
assayed. At the 45-d postpartum visit, subjects were also asked
to complete a breastfeeding questionnaire that included ques-
tions about the exclusivity of breastfeeding and formula use.
At the time of the participant’s visit to our clinic (generally late
morning), blood samples were collected by venipuncture in
sodium heparin and immediately placed on ice. Within 30 min,
samples were centrifuged (2000 · g for 10 min) at 4C to isolate
plasma, which was then aliquoted and stored at 280C until
assayed for concentrations of choline and its metabolites. Cho-
line and its metabolites were extracted from the plasma or breast
milk by using the method of Bligh and Dyer (34). Specifically,
aqueous and organic compounds were separated, analyzed, and
quantified directly by using liquid chromatography/electrospray
ionization-isotope–dilution mass spectrometry after the addition
of internal standards labeled with stable isotopes to correct for
recovery (35). In plasma, concentrations of free choline and
esterified choline (phosphatidylcholine and sphingomyelin), as
well as betaine, were measured. In milk samples, free choline,
phosphatidylcholine, sphingomyelin, betaine, phosphocholine,
and glycerophosphocholine were measured, all of which were
previously shown to be present in human milk (36).
Analyses of SNPs
Maternal blood samples were collected at the 45-d postpartum
visit by venipuncture, and peripheral lymphocytes were isolated
from blood by Ficoll-Hypaque gradient with evacuated cell
preparation tubes with sodium citrate (Becton Dickinson,
Franklin Lakes, NJ) (37, 38). Genomic DNAwas extracted with
a PureGene kit (Gentra Systems, Minneapolis, MN) according to
the manufacturer’s instructions. We genotyped participants with
respect to 370 common SNPs in a defined set of 10 genes related
to choline metabolism (30). DNA samples were genotyped for the
SNPs of interest by the UNC Mammalian Genotyping Core with
the Illumina GoldenGate oligo-specific extension–ligation assay
(39). Briefly, 3 assay oligonucleotides—2 allele specific (ASO) and
one locus specific (LSO)—were designed for each SNP locus
and scored for likelihood of success. The ASOs for each allele
and corresponding LSOs were hybridized to whole genomic
DNA from each individual and washed to remove nonhybridized
material. The ASOs and LSOs were extended across the 1–20-
base pair gap between them and ligated to form the template for
the polymerase chain reaction (PCR) with ASO fluorescent-
labeled universal primers, the product of which was hybridized to
oligonucleotides complementary to the unique address of the
LSO anchored to the bead substrate. The relative fluorescence of
each allele was quantified, and the genotype was determined.
For SNPs that failed the design score test for the bead array,
forward primers specific to each allele were designed so that the
SNP would be located at the 3# end of the priming sequence,
which allows for specific PCR products to be synthesized only if
the primer is 100% complementary to its template DNA. Primers
were designed with GeneFisher program (version 2.0)(http://
bibiserv.techfak.uni-bielefeld.de/genefisher) and purchased from
Qiagen Operon (Huntsville, AL). The PCRs were optimized for
each pair of primers, and the products were visualized on a 1.5%
agarose gel to determine the genotype.
Statistical methods
Complete data sets were not obtained from all participants.
Specifically, a plasma sample was not obtained from 4 subjects, 4
subjects did not provide breast-milk samples, and 9 participants
did not complete 3-d food records.
We used t tests to compare the placebo and supplement
groups for dietary choline and betaine intakes as well as for total
choline intake after including the amount from the supplement.
We also used t tests to compare the placebo and supplement
groups for the 6 breast-milk and 4 plasma choline metabolites.
For each of the 10 choline metabolites (6 breast milk and 4
plasma), a linear regression model was fitted with the metabolite
as the response and total choline intake as the predictor. To
determine outliers with undue influence, a model was fitted by
using all observations, and to determine outliers with undue
influence, Cook’s D (40) was computed for each. Observations
with a value of Cook’s D .4/n, where n is the number of ob-
servations used in fitting the model, were deemed to be overly
influential and were dropped. The functional form of the model
(ie, linearity) was assessed by using aggregates of cumulative
residuals (41). The normality assumption was tested by per-
forming Shapiro-Wilk’s test on the residuals generated from
fitting the model. If the normality assumption was violated,
square root and natural log transformations on the response
variable were considered. The assumptions of homoskedasticity
and independence of the residuals were tested by using the
procedure of White (42) as implemented in the SAS software
(version 9.2; SAS Institute, Chicago, IL). If the assumption of
homoskedasticity was violated, a model with weighted least
squares was used.
To test for possible confounding by age, body mass index,
parity, prenatal vitamin use, exclusivity of breastfeeding, and
supplement compliance (supplement group only), a forward-
selection procedure was used according to the Schwarz Bayesian
information criterion (43).
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We used 2 exploratory approaches to identify SNPs that may
influence choline and choline metabolite concentrations in breast
milk or plasma. In the first approach, we considered 10metabolites
(free choline, phosphatidylcholine, sphingomyelin, betaine,
phosphocholine, and glycerophosphocholine in breast milk and
free choline, phosphatidylcholine, sphingomyelin, and betaine in
plasma) and 370 SNPs. Each of the 370 SNPs was classified in 3
different ways (W-W compared with W-V compared with V-V,
W-W+W-V compared with V-V, andW-W compared withW-V +
V-V), where W is the wild-type allele, and V is the variant allele.
For each of the 3 SNP classifications and each metabolite, a linear
regression model was performed with the metabolite as the re-
sponse, and total choline intake and SNPs as predictors. The
resulting P values for all 3 possible SNP configurations were
entered using the PROC MULTTEST procedure (SAS version
9.2; SAS Institute) simultaneously to adjust for multiple testing
and determine the false discovery rate. Combinations of SNPs
that had a false discovery rate, 0.05 and a sample size5 for all
groups compared were considered statistically significant, and
consequently it was concluded that there was a difference in
metabolite across SNPs after adjusting for total choline intake.
These procedures were performed with an interaction term for
total choline intake and SNP in themodel to determinewhich SNPs
altered the relation of total choline intake to metabolite concen-
tration. All analyses were done for placebo subjects, supplement
subjects, and all subjects (placebo and supplement) combined.
Because the outliers that were discarded in the first set of
analyses may have been of significance, a second exploratory
approach was used to identify combinations of SNPs that were
shared by outliers. These combinations of SNPs may influence
the dose-response relation of total choline intake to breast-milk
and plasma choline concentrations. Specifically, a regression
analysis was performed to examine how choline intake affects
breast-milk and plasma choline and choline metabolite con-
centrations within placebo subjects, supplement subjects, and
across all subjects combined (supplement and placebo). In-
dividual participants whose values did not fall within the 95%
prediction limits were identified. We identified the variant alleles
that these outliers had in common (considering only the ho-
mozygous V-V genotypes). For example, if all of the outliers
above the 95% prediction limit in a particular regression analysis
had V-Vat SNPA and at SNP B, this combination of SNPs could
be potentially interesting. We also identified all other participants
who carried this same set of variant alleles. With the use of
regression analysis, we calculated the main effect of this set of
SNPs and the interaction effect between this set of SNPs and total
choline intake to evaluate whether individuals with this set of
variant alleles had a significantly different pattern of metabolites
in response to total choline intake. P values were adjusted by
using the false discovery rate in the PROC MULTTEST pro-
cedure (SAS version 9.2; SAS Institute). Combinations of SNPs
that had a false discovery rate ,0.01 in either the main effect or
interaction effect were considered significant.
RESULTS
Adverse events
Because the study population comprised pregnant women and
infants (both vulnerable populations), we erred on the side of
caution with respect to adverse-event reporting, even if the events
were unlikely to be related to study participation (eg, urinary tract
infection). The majority of mothers participating in this study
gave birth to healthy infants or infants with minor health concerns
such as jaundice. The most frequent adverse event that took place
in mothers was gestational diabetes (7 subjects; 4 subjects in the
choline group, 3 subjects in the placebo group) followed by
gastrointestinal disturbances (nausea, cramping, and diarrhea)
that occurred in 5 subjects (2 in the choline group, 3 in the
placebo group). The most frequent adverse event that occurred in
infants was gastrointestinal reflux (6 subjects; 2 in the choline
TABLE 1





group (n = 48)
Dietary choline (mg/d) 364 6 18 (139–671)2 338 6 14 (124–622)
Total choline for diet
plus supplement
groups (mg/d)
364 6 183 1088 6 144
Betaine (mg/d) 295 6 32 263 6 23
1 Pregnant women at ,18 wk gestation were enrolled and randomly
assigned to receive either a choline supplement (750 mg choline/d) or a pla-
cebo (corn oil). Participants took these supplements from 18 wk pregnancy
to 45 d postpartum. Participants kept 3-d food records immediately before
the 45-d postpartum study visit. Participants were asked to record all food
and beverage intakes on 2 typical weekdays and 1 weekend day. Food re-
cords were analyzed with Food Processor SQL nutrient analysis software
(version 10.3; ESHA Research, Salem, OR). Daily choline and betaine in-
takes (mg/d) were estimated for each subject by taking an average of their
3-d intake. Groups were compared by t tests.
2 Mean concentration 6 SE; range of dietary intake of choline (exclud-
ing the supplement) in parentheses (all such values).
3 Mean concentration 6 SE (all such values).
4 Significantly different from placebo group, P , 0.0001.
TABLE 2






group (n = 51)
Breast milk (nmol/mL)
Free choline 83 6 8 106 6 102
Phosphatidylcholine 107 6 7 113 6 5
Betaine 7.0 6 0.5 12.3 6 1.42
Phosphocholine 553 6 27 722 6 392
Glycerophosphocholine 388 6 25 426 6 23
Sphingomyelin 67 6 4 67 6 4
Plasma (nmol/mL)
Free choline 7.7 6 0.3 13.7 6 0.62
Phosphatidylcholine 2009 6 57 1994 6 46
Betaine 64 6 5 126 6 92
Sphingomyelin 514 6 15 506 6 11
1 All values are mean concentrations 6 SEs. Pregnant women at
,18 wk gestation were enrolled and randomly assigned to receive either
a choline supplement (750 mg choline/d) or a placebo (corn oil) from 18 wk
pregnancy to 45 d postpartum. Choline and choline metabolite concentra-
tions were measured by using liquid chromatography/mass spectrometry in
breast-milk and plasma samples collected at 45 d postpartum. Groups were
compared by t tests.
2 Significantly different from placebo group, P , 0.001.
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group, 4 in the placebo group). Results of the interim and final
safety analyses showed that there was no difference in the fre-
quency of adverse events between the supplemental choline and
placebo groups, and there was no clear evidence of a trend or
suggestion of causality of the study agent (PhosChol; Nutrasal).
In addition, the study physician observed that adverse events did
not occur more frequently among the study population relative to
a normal obstetric population.
Dietary and supplemental choline intake
All subjects began a choline- or placebo-supplement regimen at
18 wk pregnancy (on the basis of their due date) per the protocol.
The mean duration of treatment from that point until the 45-d
postpartum visit was 195 d (range: 163–215 d) in the supplemented
group and 196 d (range: 165–217 d) in the placebo group.
Daily intake of choline from the diet was estimated by
analyzing 3-d food records kept by participants (46 participants in
the placebo group, 48 participants in the supplement group)
immediately before their 45-d postpartum study visit. In the
placebo group, the dietary intake of choline ranged from 139 to
671 mg choline/d, with a mean intake of 364 mg choline/d (Table
1). In the supplement group, daily choline intake (excluding the
supplement) ranged from 124 to 622 mg choline/d, with a mean
intake of 338 mg choline/d. Mean intakes of choline and betaine
did not differ between the 2 groups. In the placebo group,
4 participants met or exceeded the AI for lactating women
(550 mg choline/d) and 3 other participants consumed an av-
erage intake that exceeded 500 mg choline/d (data not shown).
In the supplement group, only one participant consumed choline
at or above the AI for lactating women, and 2 other participants
consumed .500 mg choline/d on average (data not shown).
FIGURE 1. Influence of dietary choline intake on breast-milk choline metabolite concentrations. Pregnant women were enrolled and randomly assigned to
receive either a choline supplement (750 mg choline/d) or a placebo (corn oil) from 18 wk gestation to 45 d postpartum. Choline and choline metabolite
concentrations were measured by using liquid chromatography/mass spectrometry in breast milk collected at 45 d postpartum. Dietary intake was estimated by
using 3-d food records and adding the intake from the supplement or placebo. Plots are shown for all 6 metabolites that were measured in breast milk.
Regression models with metabolite as the response and total choline intake (diet plus supplement) as the predictor were fitted considering either placebo
subjects, supplemented subjects, or all subjects combined (3 solid lines). The following numbers of outliers (defined in Subjects and Methods) for each
metabolite were excluded: subjects who received placebo only—glycerophosphocholine (4), phosphocholine (4), phosphatidylcholine (4), sphingomyelin (3),
choline (3), and betaine (2); subjects who received the supplement only—glycerophosphocholine (3), phosphocholine (1), phosphatidylcholine (2),
sphingomyelin (3), choline (3), and betaine (3); and all subjects combined—glycerophosphocholine (5), phosphocholine (5), phosphatidylcholine
(3), sphingomyelin (5), choline (5), and betaine (7). Weighted least-squares regression was performed in the model with breast-milk phosphocholine to
overcome heteroskedasticity. To achieve normality, log transformations were made on breast-milk phosphatidylcholine, phosphocholine, betaine, and choline
concentrations. Three statistical analyses were performed for each metabolite: effect of intake on concentrations for the placebo group (indicated above the
line on the left), effect of intake plus supplement on concentrations for the supplemented group (indicated above the line on the right), and effect of intake plus
supplement on concentrations for the combined groups (indicated above the bracket). P values are indicated when differences were significant. Group sizes for
the placebo and supplement groups were 46 and 48 subjects, respectively. The R2 values for the placebo, supplement, and placebo plus supplement groups,
respectively, are as follows: for phosphocholine—0.11, 0.02, and 0.16; for glycerophosphocholine—0.003, 0.0001, and 0.006; for phosphatidylcholine—0.11,
0.008, and 0.07; for sphingomyelin—0.006, 0.003, and 0.003; for choline—0.008, 0.009, and 0.08; and for betaine—0.005, 0.003, and 0.13. +, subjects
randomly assigned to the placebo group; d, subjects randomly assigned to the choline supplement group.
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Choline and its metabolites in breast milk and plasma
Breast milk samples (n = 48 in the placebo group, n = 51 in
the supplement group) and plasma samples (n = 48 in the pla-
cebo group, n = 51 in the supplement group) were collected from
participants at 45 d postpartum and analyzed for choline and
individual choline metabolites (Table 2). Participants randomly
assigned to the supplemental choline group had, on average,
significantly higher concentrations of free choline, betaine. and
phosphocholine in breast milk than did participants in the pla-
cebo group irrespective of their dietary intake or genotype.
Moreover, participants in the supplement group had significantly
higher concentrations of free choline and betaine in their plasma
relative to participants in the placebo group irrespective of di-
etary intake and genotype. On the basis of a breastfeeding
questionnaire collected at the 45-d postpartum visit, 84 of 103
subjects (82%) exclusively breastfed, whereas 19 subjects (18%)
supplemented with formula.
Influence of total choline intake on concentrations of
choline and its metabolites in breast milk and plasma
Linear regression analyses were carried out for all of the breast
milk and plasma choline metabolites to determine whether choline
intake was a significant predictor of metabolite concentrations.
Graphsof all breast-milkmetabolites are shown inFigure1.Graphs
for all of the plasma choline metabolites are shown in Figure 2.
In the placebo group, breast-milk concentrations of phosphati-
dylcholine (P = 0.007) and plasma concentrations of choline (P =
0.0001) were significantly correlated with total intake of choline
(diet alone). In the supplement group, plasma concentrations of
choline (P = 0.03) were significantly correlated with total choline
intake. Finally, in all subjects combined, breast milk concentrations
of choline (P= 0.001), phosphatidylcholine (P = 0.02), betaine (P=
0.0003), and phosphocholine (P = 0.0001) were significantly cor-
related with the total intake of choline (diet plus supplement), as
were plasma concentrations of choline (P = 0.0001) and betaine
(P = 0.0001). For all of these significant associations, metabolite
concentrations went up as the total choline intake increased.
Plasma choline concentrations were correlated with breast-milk
choline concentrations in the placebo group (P = 0.04) and in all
subjects combined (P = 0.0001). Plasma betaine concentrations
were significantly associated with breast-milk betaine concen-
trationswhen all subjectswere considered together (P=0.0001) but
not when placebo or supplemented subjects were examined alone.
Effects of SNPs on choline metabolite concentrations in
breast milk and plasma
A list of SNPs in participants that significantly interacted (P ,
0.05) with the total choline intake on breast-milk and plasma
choline concentrations is provided in Table 3. These SNPs (either
with 1 or 2 copies of the variant allele) changed the slope of the
response curves of choline intake–breast-milk concentrations.
FIGURE 2. Influence of dietary choline intake on plasma choline metabolite concentrations. Pregnant women at,18 wk gestation were randomly assigned
to receive either a choline supplement (750 mg choline/d) or a placebo (corn oil) from 18 wk pregnancy to 45 d postpartum. Choline and choline metabolite
concentrations were measured by using liquid chromatography/mass spectrometry in plasma samples collected at 45 d postpartum. Values are plotted against
total choline intake (diet plus supplement or placebo). Plots are shown for all metabolites measured in plasma. Regression models with metabolite as the
response and total choline intake (diet plus supplement) as the predictor were fitted considering placebo subjects, supplemented subjects, or all subjects
combined (3 solid lines). The following numbers of outliers (defined in Subjects and Methods) for each metabolite were excluded: subjects who received
placebo only—choline (3), betaine (2), phosphatidylcholine (7), and sphingomyelin (4); subjects who received the supplement only—choline (2), betaine (4),
phosphatidylcholine (4), and sphingomyelin (4); and all subjects combined—choline (3), betaine (7), phosphatidylcholine (7), and sphingomyelin (7).
Weighted least-squares regression was performed in the model with plasma phosphatidylcholine to overcome heteroskedasticity. To achieve normality, log
transformations were done on plasma betaine, choline, and phosphatidylcholine concentrations. Three statistical analyses were performed for each metabolite:
the effect of intake on concentrations for the placebo group (indicated above the line on the left), the effect of intake plus the supplement on concentrations for
the supplemented group (indicated above the line on the right), and the effect of intake plus the supplement on concentrations for the combined groups
(indicated above the bracket). P values are indicated when differences were significant; group sizes for placebo and supplement groups were 46 and 48
subjects, respectively. The R2 values for placebo, supplement, and placebo plus supplement groups, respectively, are as follows: for choline—0.11, 0.15, and
0.55; for phosphatidylcholine—0.004, 0.01, and 0.0001; for betaine—0.09, 0.07, and 0.56; and for sphingomyelin—0.07, 0.02, and 0.02. +, subjects randomly
assigned to the placebo group; d, subjects randomly assigned to the choline supplement group.
DIET, SNPS, AND CHOLINE IN BREAST MILK AND PLASMA 341
These SNPs were revealed only when the placebo participants
were considered alone, and the SNPs were all in the MTHFR
gene. No significant interactions were seen in the supplement
group or in all subjects combined.
SNPs that had significant main effects in the placebo and
supplement groups, separately and combined, are listed in Table
3. These SNPs (either as W-Vor V-V) shifted the response curves
of choline intake–breast-milk concentrations up but did not
change the slope of the response curves. The 2 SNPs revealed
were in the comparisons of the supplement group and of all
subjects combined and all occurred in the PEMT gene.
Combinations of SNPs that influence breast-milk and
plasma choline and choline metabolite concentrations
A second exploratory approach identified outliers with values
that fell beyond the 95% prediction limits. Variant alleles that
these outlier participants had in common (homozygous V-V
genotype) were identified. Other participants homozygous for
these alleles were also identified and plotted on the intake-con-
centration curve to visually evaluate their response to choline
intake. Two sample plots that used this approach are shown in
Figure 3. The first plot (Figure 3A) shows breast-milk choline
concentrations compared with total choline intake in placebo
subjects. Three participants, identified with bold dots, had 5
SNPs in common: rs1076991, rs2983733, rs2987981, rs8003379,
and rs17824591. All of these occurred in the methylene tetra-
hydrofolate dehydrogenase 1 (MTHFD1) gene. All 3 of these
subjects had very high breast-milk choline concentrations; 2
subjects were outliers and the third subject had high concentra-
tion-for-intake values. In the second plot of plasma choline
(Figure 3B), 5 participants, identified with bold dots, had 2 SNPs
in common: rs2461248 (BHMT) and rs7700970 (BHMT). Four of
the 5 subjects had lower-than-average plasma choline concen-
trations, and 2 subjects were outliers. A list of all SNP groupings
that have significant effects on choline metabolite concentrations
is shown in Table 4.
DISCUSSION
The purpose of this study was to refine our understanding of
dietary requirements for choline in women who are lactating,
which is a developmental period when adequate choline is critical
for optimal infant brain development and mothers themselves are
at greater risk of choline deficiency (44). We observed that breast-
milk concentrations of choline and its metabolites were influ-
enced by maternal diet and maternal genotype. Perhaps this
explains why Zeisel et al (29) and Ilcol et al (45) reported that
lactating women have a wide range of concentrations of choline
and choline metabolites in their breast milk.
We collected and analyzed 3-d food records at 20 and 30 wk
pregnancy and 45 and 90 d postpartum and saw very little
intraindividual variation in these estimates (data not shown); thus,
the estimate of choline intake measured at 45 d postpartum was
a reasonable representation of habitual intake. In our participants,
the mean maternal dietary intake of choline (excluding the
supplement) was .33% lower than the daily recommended AI
for lactating women (24). A number of studies previously re-
ported that dietary choline intake during pregnancy was below
the recommended AI (25, 46).
Choline intake from the diet in the placebo group was directly
correlated with breast-milk phosphatidylcholine concentrations;
TABLE 3
Single nucleotide polymorphisms (SNPs) that influenced breast-milk choline metabolite concentration curves in participants given a placebo or choline
supplement1







MTHFR rs1537516 GG (34)5 GA (8) AA (0) Free Cho Interaction 20.00714 —
MTHFR rs17367629 GG (34) GA (7) AA (0) Free Cho Interaction 20.00693 —
MTHFR rs3753582 AA (34) AC (8) CC (0) Free Cho Interaction 0.007137 —
MTHFR rs3753588 GG (34) GA (8) AA (0) Free Cho Interaction 20.00714 —
MTHFR rs6687229 CC (34) CT (8) TT (0) Free Cho Interaction 20.00714 —
Supplement
PEMT rs711352 GG (22) GC (18) CC (3) Betaine Main effect — 2.0 (1.5, 2.7)
Placebo plus supplement
PEMT rs711352 GG (51) GC (30) CC (3) Betaine Main effect — 1.6 (1.3, 2.0)
1 W, wild type; V, variant; Free Cho, unesterified choline. Pregnant women at ,18 wk gestation were enrolled and randomly assigned to receive either
a choline supplement (750 mg choline/d) or a placebo (corn oil) from 18 wk pregnancy to 45 d postpartum. Participants were genotyped for 370 SNPs by using
lymphocyte DNA. Each SNP was individually tested for an interaction with dietary intake and a main effect on breast-milk and plasma choline and choline
metabolite concentrations among placebo subjects, supplement subjects, and all participants combined. Each comparison was carried out via linear regression
analysis in 3 different ways as follows: W-W compared with W-V compared with V-V, W-W + W-V compared with V-V, or W-W compared with W-V + V-V.
Comparisons were only carried out for SNPs that had a sample size 5 for all groups compared. The results from all 3 SNP configurations were entered by
using the PROC MULTTEST procedure (SAS version 9.2; SAS Institute, Chicago, IL) simultaneously.
2 SNPs with a significant interaction or main effect (P , 0.05). Note that the only significant interactions or main effects were in breast milk.
3 Change in slope indicates how much the slope of the line predicting the effect of total choline intake on metabolite changes when going from W-W to
W-V or V-V. A minus sign indicates that the slope for W-V or V-V subjects was smaller than for W-W subjects.
4 Change in least-squares mean indicates how much the least-squares mean metabolite concentration (in lmol/L) changed when going from W-W to W-V
or V-V.
5 Genotype; number of participants with the genotype in parentheses (all such values).
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phosphatidylcholine in milk is part of the milk fat globule (28).
Dietary choline was also directly correlated with plasma choline
concentrations. A dietary supplement that contained phosphati-
dylcholine (delivering 750 mg choline/d) increased choline,
betaine, and phosphocholine concentrations in breast milk (Table
2, Figure 1) and increased choline and betaine concentrations in
maternal plasma (Table 2, Figure 2). Phosphocholine is the major
water-soluble form of choline in milk because choline, once
transported into mammary epithelium, is rapidly phosphorylated
and, thereby, prevents diffusion back into maternal blood (47).
Betaine is formed from choline in the maternal liver and kidney
(48). The supplement achieved what appears to be the maximal
concentrations of choline metabolites in milk and plasma because
the slopes of the intake-concentration curves for these metabo-
lites in the supplemented group were flat (additional choline from
the diet did not further increase the metabolite concentrations).
The intake-concentration response curves for choline and betaine
in milk and plasma had similar slopes for placebo and supple-
mented groups, and the correlations between intakes and con-
centrations for these metabolites was most significant when the
placebo and supplemented groups were combined (larger n).
With the use of this approach, there was a significant correlation
between intakes and milk concentrations for phosphocholine,
phosphatidylcholine, choline, and betaine. We suggest that the
response range for these metabolites is linear from 150 to 750
mg intake. Thus, a variation in dietary intake and diet supple-
mentation can alter breast-milk composition.
As discussed earlier, common genetic variations in humans in
many of the genes that code for the enzymes of choline and folate
metabolism influence the dietary requirement for choline (30,
31). Some of these genetic variations are extremely common and
are present in the majority of the population (30). To our
knowledge, we are the first to examine whether SNPs in choline
or folate metabolism genes influence the composition of breast
milk. There have been no published methods for analyzing the
effects of SNPs on breast-milk composition. For this reason, we
report on 2 different approaches. The first characterized the
(response) curves of the diet intake (dose)–breast-milk concen-
trations and determines whether a given SNP altered the slope of
the curve or whether the curve was shifted up or down at all
intakes. The second approach identified outliers who fell outside
of the 95% CI for the mean dose-response curve and asked
whether these individuals shared SNPs in common. Our analyses
were complicated by linkage disequilibrium; many SNPs are
inherited together and form a haplotype (49, 50). Although we
considered individual SNPs in our analyses, the effects on breast-
milk metabolites may be the result of interactions between SNPs.
SNPs can have functional effects onmetabolism in a number of
ways. An exonic SNP that results in a nonsynonymous amino
acid substitution could alter the substrate binding site of an
enzyme and result in reduced affinity; this SNP would be as-
sociated with a decrease in the dose-response curves. An exonic
SNP that results in a nonsynonymous amino acid substitution also
could result in a reduction in the amount of functioning enzyme
protein and reduce the total capacity of the enzyme such that it is
saturated at low substrate concentrations and, again, cause
a decrease in the slope of the dose-response curves. An SNP in
a transcription factor binding site in the gene’s promoter region
could also reduce the amount of functioning enzyme protein and,
thus, decrease the slope of the dose-response curve. An SNP in an
inhibitory site in the promoter would have the opposite effect. It
would increase the amount of functioning enzyme protein and
increase capacity and, thereby, increase the slope of the dose-
response curve. If an SNP altered an inhibitory binding site on
the protein itself (eg, one that mediates product inhibition of the
enzyme), the dose-response curve might shift at all points in the
dose-response curve. An SNP that altered the binding of an
activating cofactor would likely shift the curves in the opposite
direction. We observed that a number of SNPs altered the slope of
the diet intake compared with breast-milk concentration curves
(Table 3), whereas other SNPs shifted these curves up but did not
alter their slope (Table 3).
The effects of some SNPs might be apparent in the placebo
group, whereas others might be apparent only in the supple-
mented group, and combining both groups in analyses might
sometimes obscure these effects. For example, some SNPs could
alter the Michaelis constant of enzymes and change the shape of
the Michaelis-Menten curve such that differences in enzyme
activity between wild-type and variant alleles would only be
apparent at lower substrate concentrations. These SNPs (en-
zymes) would look very different at low choline intakes (placebo)
FIGURE 3. Outlier approach: participants with breast-milk choline
metabolite concentrations that were beyond the 95% prediction limits for
the mean shared common single nucleotide polymorphisms (SNPs). A: Plot
of breast-milk choline concentrations compared with total choline intake in
all participants. Three participants, identified with bold dots, had 5 SNPs in
common: rs1076991, rs2983733, rs2987981, rs8003379, and rs17824591.
All of these SNPs occurred in the methylene tetrahydrofolate dehydrogenase
1 (MTHFD1) gene. All 3 of these subjects had very high breast-milk choline
concentrations, and 2 of these subjects were outliers. A linear regression model
was used to compare these 3 subjects with the rest of the subjects. B: Plot of
plasma choline concentrations compared with total choline intake in all
participants. Five participants, identified with bold dots, had 2 SNPs in
common: rs2461248 and rs7700970, both of which were in the BHMT gene.
Four of the 5 subjects had lower than average plasma choline concentrations,
and 2 of the subjects were outliers. A linear regression model was used to
compare these 5 subjects with the rest of the subjects. +, represents participants
who did not carry the common set of SNPs.
DIET, SNPS, AND CHOLINE IN BREAST MILK AND PLASMA 343
but would look the same at high concentrations (supplemented).
In contrast, if there are SNPs that affect the maximum enzyme
velocity of enzymes and not the Michaelis constant, differences
in enzyme activity between wild-type and variant alleles would
only be apparent at higher substrate concentrations. These SNPs
(enzymes) would look the same at low choline intakes (placebo)
but would look very different at high choline intakes (supple-
mented). For example, such an SNP could occur in a gene that
encodes a choline transporter enzyme. If the SNP reduced the
function of the enzyme, little difference may be evident between
individuals when choline intake is low because the transporter
would not be saturated. However, as intake increases and exceeds
the capacity of the transporter, the effect of the SNP would
become apparent. Combining the placebo and supplement groups
for either type of SNPwould result in a loss of sensitivity to detect
these types of genetic variants.
We only identified one gene, MTHFR, for which SNPs altered
the slope of the intake-concentration curve for choline (Table 3).
Genetically modified mice with defective methylenetetrahy-
drofolate reductase (MTHFR) activity become choline deficient
(51), and 15–30% of humans have genetic polymorphisms that
alter the activity of this enzyme (52, 53). We identified only one
gene, PEMT, for which SNPs shifted the intake-concentration
curve for breast-milk betaine concentrations upward (Table 3).
PEMT catalyzes the de novo biosynthesis of choline in the liver.
The PEMT gene is very polymorphic, but only a few functional
SNPs have been identified (30, 54, 55). We expected that
a functional SNP in PEMT would shift the intake-concentration
curve for breast-milk betaine concentrations in the opposite di-
rection from what was observed because individuals with de-
fective PEMT should become choline deficient and make less
betaine.
The outlier approach generated groupings of a number of SNPs
that were shared by a small number of subjects who fell outside
the 95%CI for the mean. For some of these groupings, most or all
individuals had changes in a similar direction. We suggest that
this approach can be used to generate testable hypotheses about
SNP-metabolism relations. Because the number of subjects in the
current study was small, further studies that selectively recruit
such subjects need to be performed to achieve the needed power
to detect significant effects.
This study had a number of limitations. We examined the
relation between choline intake and milk metabolite concen-
trations at only 45 d postpartum, which is when women should be
producing mature breast milk. Most, but not all, of the women
were exclusively breastfeeding at this time. As discussed, we
estimated habitual dietary intake from a series of 3-d food-intake
records. The universal use of prenatal vitamins (with folic acid)
may have obscured some effects/findings. All breast-milk sam-
ples were collected first thing in the morning upon rising
TABLE 4








for set of SNPs
Main effect of
this set of SNPs
Breast milk






Choline Placebo High (2) P = 0.0032






3 P = 0.0008
Plasma
Choline Placebo plus supplement Low (2) rs2461248 (BHMT)
rs7700970 (BHMT)
5 P = 0.0008









2 P = 0.0008
1 Pregnant women at,18 wk gestation were randomly assigned to receive either a choline supplement (750 mg choline/d) or a placebo (corn oil) from 18
wk pregnancy to 45 d postpartum and were genotyped for 370 SNPs by using lymphocyte DNA. Regression analyses were performed to determine how breast-
milk and plasma choline and choline metabolite concentrations were affected by total choline intake within placebo subjects, supplement subjects, and across
all subjects combined. Individual participants whose values did not fall within the 95% prediction limits were identified as outliers. We identified the set of
SNPs that these upper or lower outliers had in common (considering only the homozygous variant V-V genotype). We identified all subjects who had this set of
SNPs (including the outliers) and calculated the main effect of this set of SNPs and the interaction effect between this set of SNPs and total choline intake. The
sets of SNPs that had P , 0.01 in a main effect are listed. No set of SNPs had a significant interaction effect.
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(between 0500 and 1000); however, blood was sampled when the
participant visited our facility that day, which was generally in the
late morning, and the sample was not a fasting sample. We may
have detected additional differences with a more stringent pro-
tocol. Similarly, if a larger number of subjects were included in
the study, we may have identified additional SNPs of interest.
Despite these limitations, we made a number of observations that
can guide future studies.
In conclusion, we observed that breast-milk concentrations of
choline and metabolites can be influenced by diet and dietary
supplements. This is important because dietary intake of choline
is low relative to the recommended AI in pregnant and lactating
women (only 5% of our subjects consumed diets that met or
exceeded the AI for choline). We observed that a dietary sup-
plement of phosphatidylcholine (that contained 750 mg choline)
had no adverse effects and was well tolerated by pregnant and
lactating women. Also, we conducted exploratory studies on the
effects that genetic variations had on breast-milk compositions.
We observed that the effects of identified SNPs in genes of
choline and folate metabolism are complex, but these effects alter
the dose (total choline intake)-response (breast-milk or plasma
concentration) relation and can significantly change the com-
position of breast milk. Because these gene variations are ex-
tremely common, it may be appropriate to consider them when
developing individualized diets or population guidelines.
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